Annual report pursuant to Section 13 and 15(d)

NON CONTROLLING INTEREST (Tables)

v3.24.1
NON CONTROLLING INTEREST (Tables)
12 Months Ended
Dec. 31, 2023
ROYALTY OBLIGATIONS NET  
Schedule of net loss attributable to non-controlling interest

 

 

BioCorRx

Pharmaceuticals,

Inc.

 

 

Joseph

DeSanto

MD

 

Net loss

 

$ (7,384 )

 

$ (5,113 )

Average Non-controlling interest percentage of profit/losses

 

 

24.2 %

 

 

35.0 %

Net loss attributable to the non-controlling interest

 

$ (1,787 )

 

$ (1,790 )

 

 

BioCorRx

Pharmaceuticals,

Inc.

 

 

Joseph

DeSanto

MD

 

Net loss

 

$ (18,782 )

 

$ (8,211 )

Average Non-controlling interest percentage of profit/losses

 

 

24.2 %

 

 

35.0 %

Net loss attributable to the non-controlling interest

 

$ (4,545 )

 

$ (2,874 )
Schedule of changes in non-controlling interest

Balance, December 31, 2022

 

$ (125,257 )

Net loss attributable to the non-controlling interest

 

 

(3,577 )

Balance, December 31, 2023

 

 

(128,834 )

Balance, December 31, 2021

 

$ (117,838 )

Net loss attributable to the non-controlling interest

 

 

(7,419 )

Balance, December 31, 2022

 

 

(125,257 )